Mark C Genovese (Mark Genovese)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 30

Top Topics

Rheumatoid Arthritis

Top Venues

Arthritis & rheumatology (Hoboken, N.J.)

The Journal of rheumatology

Annals of the rheumatic diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Matthew C Baker, Sarah Kavanagh, Stanley B Cohen, Alan K Matsumoto, Ara Dikranian, John Tesser, Alan Kivitz, Konstantinos Alataris, Mark C Genovese
A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Yoshiya Tanaka, Mark C Genovese, Hironori Matsushima
Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives. Patient preference and adherence 17 (2023)
Matthew C Baker, Konstantinos Alataris, Mark C Genovese
Reply. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Liana Fraenkel, Joan M Bathon, Bryant R England, E William St Clair, Thurayya Arayssi, Kristine Carandang, Kevin D Deane, Mark C Genovese, Kent Kwas Huston, Gail Kerr, Joel M Kremer, Mary C Nakamura, Linda A Russell, Jasvinder A Singh, Benjamin J Smith, Jeffrey A Sparks, Shilpa Venkatachalam, Michael E Weinblatt, Mounir Al-Gibbawi, Joshua F Baker, Kamil E Barbour, Jennifer L Barton, Laura C Cappelli, Fatimah Chamseddine, Michael D George, Sindhu R Johnson, Lara Kahale, Basil S Karam, Assem M Khamis, Iris Y Navarro-Millán, Reza Mirza, Pascale Schwab, Namrata Singh, Marat Turgunbaev, Amy S Turner, Sally G Yaacoub, Elie A Akl
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis care & research 73 (7) (2021)
Kevin L Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, Alan Kivitz, Franziska Matzkies, Mark C Genovese, Deyuan Jiang, Kun Chen, Beatrix Bartok, Angelika Jahreis, Robin Besuyen, Gerd-Rüdiger R Burmester, Jacques-Eric Gottenberg
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Annals of the rheumatic diseases (2021)
Liana Fraenkel, Joan M Bathon, Bryant R England, E William St Clair, Thurayya Arayssi, Kristine Carandang, Kevin D Deane, Mark C Genovese, Kent Kwas Huston, Gail Kerr, Joel M Kremer, Mary C Nakamura, Linda A Russell, Jasvinder A Singh, Benjamin J Smith, Jeffrey A Sparks, Shilpa Venkatachalam, Michael E Weinblatt, Mounir Al-Gibbawi, Joshua F Baker, Kamil E Barbour, Jennifer L Barton, Laura C Cappelli, Fatimah Chamseddine, Michael D George, Sindhu R Johnson, Lara Kahale, Basil S Karam, Assem M Khamis, Iris Y Navarro-Millán, Reza Mirza, Pascale Schwab, Namrata Singh, Marat Turgunbaev, Amy S Turner, Sally G Yaacoub, Elie A Akl
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 73 (7) (2021)
Mark C Genovese, Patrick Durez, Roy M Fleischmann, Yoshiya Tanaka, Daniel E Furst, Hisashi Yamanaka, Elena Korneva, Igor Vasyutin, Tsutomu Takeuchi
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. European journal of rheumatology (2021)
Masayoshi Harigai, Kevin Winthrop, Tsutomu Takeuchi, Tsu-Yi Hsieh, Yi-Ming Chen, Josef S Smolen, Gerd-Rüdiger R Burmester, Chad Walls, Wen-Shuo Wu, Christina Dickson, Ran Liao, Mark C Genovese
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD open 6 (1) (2021)
Josef S Smolen, Jung-Yoon Choe, Michael E Weinblatt, Paul Emery, Edward Keystone, Mark C Genovese, Gihyun Myung, Evelyn Hong, Inyoung Baek, Jeehoon Ghil
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD open 6 (1) (2021)
Mark C Genovese, Herbert Kellner, Yasumasa Arai, Rafael Muniz, Rieke E Alten
Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. RMD open 6 (1) (2021)
Evgeniy Nasonov, Saeed Fatenejad, Eugen Feist, Mariana G Ivanova, Elena Korneva, Diana G Krechikova, Aleksey L Maslyanskiy, Mikhail Samsonov, Rumen Malinov Stoilov, Elena V Zonova, Mark C Genovese
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Annals of the rheumatic diseases (2021)
Arthur Kavanaugh, Rene R Westhovens, Kevin L Winthrop, Susan J Lee, YingMeei Tan, Di An, Lei Ye, John S Sundy, Robin Besuyen, Luc Meuleners, Mykola Stanislavchuk, Alberto J Spindler, Maria Greenwald, Rieke E Alten, Mark C Genovese
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. The Journal of rheumatology 48 (8) (2021)
Mark C Genovese, Gerd R Burmester, Owen Hagino, Karthinathan Thangavelu, Melitza Iglesias-Rodriguez, Gregory St John, Miguel A González-Gay, Thomas Mandrup-Poulsen, Roy Fleischmann
Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis research & therapy 22 (1) (2020)
Mark C Genovese, Roy Fleischmann, Alan Kivitz, Eun-Bong Lee, Hubert van Hoogstraten, Toshio Kimura, Gregory St John, Erin K Mangan, Gerd R Burmester
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis research & therapy 22 (1) (2020)
Yashaar Chaichian, Mark C Genovese, Michael H Weisman
The road to rheumatoid arthritis prevention: challenges and opportunities. Clinical rheumatology 39 (5) (2020)
Mark C Genovese, Alberto Spindler, Akira Sagawa, Won Park, Anna Dudek, Alan Kivitz, Jeannie Chao, Lai Shan Melanie Chan, Jennifer Witcher, William Barchuk, Ajay Nirula
Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study. The Journal of rheumatology 48 (7) (2020)
Rieke E Alten, Colin Markland, Malcolm Boyce, Kazuki Kawakami, Rafael Muniz, Mark C Genovese
Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. International journal of rheumatic diseases 23 (11) (2020)
Anita Boyapati, Sergio Schwartzman, Jérôme Msihid, Ernest Choy, Mark C Genovese, Gerd R Burmester, Gordon Lam, Toshio Kimura, Jonathan Sadeh, David M Weinreich, George D Yancopoulos, Neil M H Graham
Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis & rheumatology (Hoboken, N.J.) 72 (9) (2020)
Kevin L Winthrop, Masayoshi Harigai, Mark C Genovese, Stephen Lindsey, Tsutomu Takeuchi, Roy M Fleischmann, John D Bradley, Nicole L Byers, David L Hyslop, Maher Issa, Atsushi Nishikawa, Terence P Rooney, Sarah Witt, Christina L Dickson, Josef S Smolen, Maxime Dougados
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the rheumatic diseases 79 (10) (2020)
Philip J Mease, Mark C Genovese, Michael E Weinblatt, Paul M Peloso, Kun Chen, Ahmed A Othman, Yihan Li, Heikki T Mansikka, Amit Khatri, Neil Wishart, John Liu
Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. Arthritis & rheumatology (Hoboken, N.J.) 70 (11) (2019)
Anna Postolova, Megan L Troxell, Irene L Wapnir, Mark C Genovese
Methotrexate in the Treatment of Idiopathic Granulomatous Mastitis. The Journal of rheumatology 47 (6) (2019)
Roy M Fleischmann, Mark C Genovese, Jeffrey V Enejosa, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew Ostor, Yihan Li, In-Ho Song
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Annals of the rheumatic diseases 78 (11) (2019)
Roy M Fleischmann, Aileen L Pangan, In-Ho Song, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew J Ostor, Yihan Li, Yijie Zhou, Ahmed A Othman, Mark C Genovese
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.) 71 (11) (2019)
Gerd-Rüdiger R Burmester, Vibeke Strand, Andrea Rubbert-Roth, Howard Amital, Tatiana Raskina, Antonio Gómez-Centeno, Claudia Pena-Rossi, Leon Gervitz, Karthinathan Thangavelu, Gregory St John, Susan Boklage, Mark C Genovese
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD open 5 (2) (2019)
Mark C Genovese, Désirée Mfm van der Heijde, Yong Lin, Gregory St John, Sheldon Wang, Hubert van Hoogstraten, Juan José Gómez-Reino, Alan Kivitz, José Antonio Maldonado-Cocco, Bruno Seriolo, Marina Stanislav, Gerd-Rüdiger R Burmester
Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD open 5 (2) (2019)
Charles Peterfy, Julie C DiCarlo, Paul Emery, Mark C Genovese, Edward C Keystone, Peter C Taylor, Doug E Schlichting, Scott D Beattie, Monica Luchi, William Macias
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. The Journal of rheumatology 46 (8) (2019)
Mark C Genovese, Michael E Weinblatt, Jacob A Aelion, Heikki T Mansikka, Paul M Peloso, Kun Chen, Yihan Li, Ahmed A Othman, Amit Khatri, Nasser S Khan, Robert J Padley
ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study. Arthritis & rheumatology (Hoboken, N.J.) 70 (11) (2018)
E William St Clair, Alan N Baer, Chungwen Wei, Ghaith Noaiseh, Anne Parke, Andreea Coca, Tammy O Utset, Mark C Genovese, Daniel J Wallace, James McNamara, Karen Boyle, Lynette Keyes-Elstein, Jeffrey L Browning, Nathalie Franchimont, Kira Smith, Joel M Guthridge, Ignacio Sanz, Judith A James, null null
Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.) 70 (9) (2018)
Josef S Smolen, Mark C Genovese, Tsutomu Takeuchi, David L Hyslop, William L Macias, Terence Rooney, Lei Chen, Christina L Dickson, Jennifer Riddle Camp, Tracy E Cardillo, Taeko Ishii, Kevin L Winthrop
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. The Journal of rheumatology 46 (1) (2018)
Mark C Genovese, Joel M Kremer, Ronald F van Vollenhoven, Rieke Alten, Juan Jose Scali, Ariella Kelman, Sophie Dimonaco, Laura Brockwell
Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 69 (9) (2017)